The brown envelope arrives unsolicited, usually every two years. Inside is a faecal immunochemical test (FIT) kit, a simple plastic device for collecting a small stool sample. The instructions are clear: collect, seal, post. For millions of UK residents aged 60 to 74—and soon from age 50—this routine step represents one of the most effective cancer screening tools. Yet what happens after a positive result reveals a system under severe strain.

According to NHS England data, the average wait for a colonoscopy following a positive FIT result now exceeds three months, well beyond the 62-day target for cancer diagnosis and treatment. A survey by Bowel Cancer UK in late 2024 found that one in four patients waited longer than 18 weeks. The screening programme itself is a triumph; the diagnostic pathway that follows is a bottleneck.

The envelope lands, then the waiting begins

The FIT kit detects microscopic blood in stool, an early sign of bowel cancer or precancerous polyps. It is highly sensitive and specific, and participation has hovered around 72% nationally. When a result is positive—about 1 in 30 tests—the next step is a colonoscopy, where a camera on a flexible tube examines the large bowel.

But that next step has become a hurdle. As of early 2025, the median wait for a colonoscopy after a positive FIT was 14 weeks, according to the Bowel Cancer UK survey. Some patients reported waits of 20 weeks or more. The NHS target of 62 days from referral to treatment is routinely missed in many trusts.

One patient, a 68-year-old retired teacher from Manchester, told the charity she waited 18 weeks for her scope. “I checked the post every day for the appointment letter,” she said. “When it finally came, I’d already convinced myself it was cancer.” Her polyp was benign, but the anxiety took a toll.

Another, a 72-year-old man from Cornwall, was told by his GP to call back if symptoms worsened. He presented to A&E three months later with a bowel obstruction and was diagnosed with stage III cancer. He had returned his FIT kit promptly and received a positive result but never got a colonoscopy appointment before his emergency.

These stories are not isolated. A 2024 study published in The Lancet Gastroenterology & Hepatology analysed data from over 10,000 patients and found that those waiting more than 12 weeks for colonoscopy after a positive FIT had a 40% higher likelihood of being diagnosed at stage III or IV compared to those scoped within four weeks. The study controlled for age, sex, and FIT level, suggesting the delay itself contributes to stage progression.

Yet some clinicians argue that not all delays are equal. Dr. Michael Chen, a colorectal surgeon in Birmingham, points out that patients with very high FIT levels—above 400 µg/g—are often fast-tracked, while those with lower levels may wait longer without harm. “The risk is not uniform,” he says. “A one-size-fits-all target may not be the best approach.” This view, however, is contested by patient groups who note that even low-level FIT results can indicate cancer.

From screening triumph to diagnostic bottleneck

The UK bowel cancer screening programme began in 2006 using guaiac-based tests, replaced by the more accurate FIT in 2019. The programme now invites everyone aged 60–74, with plans to lower the starting age to 50. Participation is among the highest in Europe, and the programme is credited with detecting cancers earlier, when they are more treatable.

But the success of screening has created a demand for colonoscopy that the NHS cannot meet. The number of colonoscopies performed annually rose from around 500,000 in 2010 to over 800,000 by 2023. Yet the endoscopy workforce has not kept pace. A 2023 report from the British Society of Gastroenterology estimated a shortfall of 200 full-time equivalent endoscopists.

Pre-pandemic backlogs never fully cleared. During COVID-19, endoscopy units were redeployed for emergency care, and many patients had their procedures postponed. The backlog grew deeper. A Freedom of Information request by the BBC in 2024 found that some trusts had waiting lists of over 12 months for routine colonoscopies, and even urgent referrals—those with positive FIT or symptoms—waited weeks.

“We are seeing the consequences of a successful screening programme that has grown faster than the diagnostic capacity,” said Dr. Helen Roberts, a gastroenterologist in Leeds. “Patients are left in limbo, and that limbo can have serious consequences.”

The trade-off is stark: expanding screening saves lives in the long run by catching cancers earlier, but the short-term strain on colonoscopy services can lead to delayed diagnoses. A 2023 modelling study by the University of Cambridge estimated that lowering the screening starting age to 50 would prevent an additional 1,200 deaths per year but would require a 25% increase in colonoscopy capacity—a target the NHS has not yet met.

Patient stories from the gap

Bowel Cancer UK’s 2024 survey of over 1,000 patients with a positive FIT result found that 60% reported significant anxiety while waiting for their colonoscopy. Many said they avoided planning holidays or social events, worried they would miss the appointment. Some called their GP repeatedly, only to be told the wait was normal.

One respondent, a 65-year-old woman from Bristol, said she was told her wait would be “about 12 weeks” but it stretched to 22. When she finally had the scope, a 2 cm adenoma was removed. “It might have been nothing, but I’ll never know if that delay mattered,” she said. “The not knowing was the worst.”

Another patient, a 59-year-old man from Glasgow, had a positive FIT in March 2024. His colonoscopy was scheduled for August, but he developed symptoms in June—blood in stool and weight loss. He called his GP, who advised him to wait for the appointment. By the time of his scope, he had a stage III tumour. “If I had been scoped earlier, maybe it would have been stage I or II,” he said. “I think about that every day.”

Such delays can lead to stage shift. A modelling study by the University of Sheffield, presented at the 2024 National Cancer Research Institute conference, estimated that a 12-week delay in colonoscopy after a positive FIT could increase the proportion of cancers diagnosed at stage III or IV by 5–10%. For every 1,000 people screened, that could mean 2–4 extra deaths.

Emergency presentations remain stubbornly common. Despite screening, about 20% of bowel cancers are still diagnosed via A&E, often at a late stage. The gap between screening and colonoscopy may be one reason. A 2025 analysis by Cancer Research UK found that patients diagnosed via emergency routes had a five-year survival rate of just 30%, compared to 80% for those diagnosed through screening.

Why the backlog persists despite political promises

The root causes are multiple. The endoscopist workforce is ageing, and training new consultants takes at least five years. The NHS has invested in training hubs, but the output is not yet meeting demand. Nurses and other non-medical endoscopists have been trained, but they are still a minority of the workforce.

Equipment is another factor. Colonoscopes are expensive and require regular maintenance. During the pandemic, many were sent for repair and not returned for months. Some trusts have adopted single-use scopes, which eliminate turnaround time but cost more per procedure. A 2024 audit by the Royal College of Physicians found that 15% of endoscopy units had equipment downtime exceeding 10% of scheduled sessions.

Funding has been ring-fenced for cancer diagnostics, but critics argue it is not enough. The NHS Long Term Plan promised £2.3 billion for cancer services by 2025, but much of that went to radiotherapy and chemotherapy, not endoscopy. A 2023 report by the Public Accounts Committee noted that the Department of Health could not demonstrate value for money from the additional funding.

Political promises have not translated into shorter waits. The 62-day target has been missed nationally since 2015. In 2024, only 65% of patients started treatment within 62 days of referral, down from 80% in 2019. The target was officially suspended during COVID-19 but has not been reinstated with enforcement.

Some argue that the 62-day target is itself part of the problem. “It treats the entire pathway as a black box,” says Dr. Roberts. “We need transparency at each step: how long from FIT result to referral, from referral to scope, from scope to diagnosis. Without that, we can’t fix the bottlenecks.”

What a longer wait means for survival

Bowel cancer is highly curable if caught early. Five-year survival exceeds 90% for stage I disease but drops to around 10% for stage IV. The window between a positive FIT and colonoscopy is a critical opportunity to catch cancer at an early stage.

A 2022 study in the British Journal of Surgery analysed data from over 50,000 patients and found that each four-week delay in colonoscopy after a positive FIT was associated with a 6% increase in the odds of a more advanced stage at diagnosis. The effect was most pronounced for delays beyond eight weeks.

NHS England acknowledges the risk but has not set a specific target for colonoscopy wait times after a positive FIT. The 62-day target covers the entire pathway from referral to treatment, but many argue that a separate target for diagnostic scopes is needed.

“The system is not designed for the volume of positive FIT results we now see,” said Dr. Roberts. “We need to rethink the pathway, not just add more lists.”

Counter-arguments exist. Some clinicians contend that the anxiety of waiting, while real, does not always translate to worse outcomes. They point to studies showing that polyps grow slowly and that a delay of a few months may not affect prognosis for many patients. But this view is challenged by evidence that even small adenomas can progress, and that the psychological toll of waiting is itself a harm.

“We shouldn’t dismiss the mental health impact,” says Dr. Chen. “Patients are terrified, and that fear is rational. We need to acknowledge it and address it, even if the clinical risk is low for some.”

Small fixes and systemic overhaul

Several innovations are being tested. Digital triage tools, such as the NHS’s “e-Referral” system, aim to prioritise patients at highest risk based on FIT level and symptoms. Those with a very high FIT result (over 400 µg/g) are offered a colonoscopy within two weeks, while those with lower levels may be scheduled for a routine list.

Community diagnostic centres (CDCs), part of the NHS’s elective recovery plan, have added endoscopy capacity outside hospitals. As of early 2025, there were over 100 CDCs offering colonoscopy, but their utilisation varies. Some run only daytime lists, while others have added weekend sessions.

Single-use colonoscopes, though more expensive per procedure, eliminate the need for reprocessing and reduce turnaround time. A pilot at University College London Hospitals found that using single-use scopes for urgent cases cut the wait from referral to scope by 30%. However, widespread adoption is limited by cost and environmental concerns.

The National Endoscopy Training Academy, launched in 2025, aims to train 500 new endoscopists over five years. The programme includes simulated training and mentorship, and early results from the first cohort are promising. But even if successful, it will take years to close the gap.

Another approach is the use of CT colonography (virtual colonoscopy) as an alternative for patients who cannot tolerate or access conventional colonoscopy. A 2024 study in Radiology found that CT colonography had a sensitivity of 90% for polyps over 1 cm, though it requires bowel preparation and exposes patients to radiation. Some trusts are using it to triage patients, reducing demand for optical colonoscopy by about 15%.

Yet these fixes are incremental. A more radical proposal, floated by some health economists, is to shift the screening paradigm itself. Instead of inviting everyone in an age group, they argue, the NHS could use risk stratification tools—such as genetic markers, lifestyle factors, and previous FIT results—to target screening to those at highest risk. A 2025 pilot in the East of England is testing this approach, but critics say it could miss cancers in lower-risk groups and increase health inequalities.

“Risk stratification sounds efficient, but it could widen the gap between those who engage with the system and those who don’t,” says Dr. Roberts. “Screening is meant to be universal.”

What you can do while the system catches up

If you receive a FIT kit, return it promptly. The test is free, simple, and the best way to catch bowel cancer early. If your result is positive, expect a call from your GP or the screening centre. Ask about the expected wait for colonoscopy and whether you can be placed on a cancellation list.

Be aware of symptoms that warrant earlier attention: persistent change in bowel habit, blood in stool, unexplained weight loss, or abdominal pain. A negative FIT does not rule out cancer, especially if symptoms persist. In that case, ask your GP about direct-access colonoscopy, which some trusts offer for patients with symptoms but no positive FIT.

Patient advocacy groups like Bowel Cancer UK and Beating Bowel Cancer provide support and updates on waiting times. They also campaign for better services and can help you navigate the system.

While the NHS works to address the backlog, individual vigilance remains important. The screening programme is a powerful tool, but it is only as good as the diagnostic pathway that follows.

In the meantime, researchers continue to explore alternatives. Liquid biopsy tests that detect circulating tumour DNA in blood are in early trials, but they are not yet ready for routine use. If validated, they could one day reduce the need for colonoscopy in some patients, but that is years away.

The gap between screening and diagnosis is not unique to bowel cancer. Similar bottlenecks exist for lung cancer screening with CT scans and for cervical cancer follow-up after abnormal smears. The NHS faces a system-wide challenge: how to match diagnostic capacity to the demand created by successful screening. Until that is solved, the brown envelope will remain a symbol of hope and frustration.

This article is for informational purposes only and does not constitute personalised medical advice. If you have concerns about bowel cancer, consult a healthcare professional.